Nurix Therapeutics (NRIX) Stock Forecast & Price Target

Compare

530 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NRIX Analyst Ratings

Strong Buy

14 Buy

2 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Nurix

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$27.53

▲(48.65% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $27.53 with a high forecast of $41.00 and a low forecast of $12.00. The average price target represents a 48.65% change from the last price of $18.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","16.5":"$16.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.5,25,33.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.91,18.763076923076923,20.616153846153846,22.46923076923077,24.322307692307692,26.175384615384615,28.02846153846154,29.88153846153846,31.734615384615385,33.58769230769231,35.440769230769234,37.293846153846154,39.14692307692307,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.91,17.72692307692308,18.543846153846154,19.360769230769233,20.177692307692308,20.994615384615386,21.81153846153846,22.62846153846154,23.445384615384615,24.262307692307694,25.07923076923077,25.896153846153847,26.713076923076926,{"y":27.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.91,16.532307692307693,16.154615384615386,15.776923076923078,15.399230769230769,15.021538461538462,14.643846153846154,14.266153846153847,13.888461538461538,13.510769230769231,13.133076923076922,12.755384615384616,12.377692307692307,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$41.00

Average Price Target$27.53

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

$21→$30

Buy

61.99%

Upside

Reiterated

12/16/25

Nurix Therapeutics (NRIX) Receives a Buy from Wells Fargo

Joseph Catanzaro

Mizuho Securities

$24→$30

Buy

61.99%

Upside

Reiterated

12/10/25

Mizuho Securities Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

Robert Burns

H.C. Wainwright

$28→$31

Buy

67.39%

Upside

Reiterated

12/10/25

Nurix Therapeutics price target raised to $31 from $28 at H.C. WainwrightNurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright

Gregory Renza

Truist Financial

Buy

―

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP) and Nurix Therapeutics (NASDAQ: NRIX)

Jeet Mukherjee

BTIG

$27→$30

Buy

61.99%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

$15

Hold

-19.01%

Downside

Reiterated

12/09/25

Balanced Outlook on Nurix Therapeutics: Promising Developments Amid Uncertainties

Gil Blum

Needham

$26

Buy

40.39%

Upside

Reiterated

12/08/25

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Nurix Therapeutics (NRIX)

Stephen Willey

Stifel Nicolaus

$33

Buy

78.19%

Upside

Reiterated

12/08/25

Stifel Nicolaus Remains a Buy on Nurix Therapeutics (NRIX)

Biren Amin

Piper Sandler

$32

Buy

72.79%

Upside

Reiterated

12/08/25

Nurix Therapeutics (NRIX) Gets a Buy from Piper Sandler

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$41

Buy

121.38%

Upside

Reiterated

12/04/25

Nurix Therapeutics (NRIX) Gets a Buy from Jefferies

Brian Abrahams

RBC Capital

$29

Buy

56.59%

Upside

Reiterated

11/19/25

RBC Capital Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

Tessa Romero

J.P. Morgan

$30→$22

Buy

18.79%

Upside

Reiterated

11/18/25

Nurix Therapeutics price target lowered to $22 from $30 at JPMorganNurix Therapeutics price target lowered to $22 from $30 at JPMorgan

David Dai

UBS

$26→$23

Buy

24.19%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)

Matthew Biegler

Oppenheimer

$28

Buy

51.19%

Upside

Reiterated

11/07/25

Nurix Therapeutics (NRIX) Gets a Buy from Oppenheimer

Faisal Khurshid

Leerink Partners

$12

Hold

-35.21%

Downside

Reiterated

10/23/25

Leerink Partners Sticks to Their Hold Rating for Nurix Therapeutics (NRIX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

$21→$30

Buy

61.99%

Upside

Reiterated

12/16/25

Nurix Therapeutics (NRIX) Receives a Buy from Wells Fargo

Joseph Catanzaro

Mizuho Securities

$24→$30

Buy

61.99%

Upside

Reiterated

12/10/25

Mizuho Securities Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

Robert Burns

H.C. Wainwright

$28→$31

Buy

67.39%

Upside

Reiterated

12/10/25

Nurix Therapeutics price target raised to $31 from $28 at H.C. WainwrightNurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright

Gregory Renza

Truist Financial

Buy

―

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP) and Nurix Therapeutics (NASDAQ: NRIX)

Jeet Mukherjee

BTIG

$27→$30

Buy

61.99%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

$15

Hold

-19.01%

Downside

Reiterated

12/09/25

Balanced Outlook on Nurix Therapeutics: Promising Developments Amid Uncertainties

Gil Blum

Needham

$26

Buy

40.39%

Upside

Reiterated

12/08/25

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Nurix Therapeutics (NRIX)

Stephen Willey

Stifel Nicolaus

$33

Buy

78.19%

Upside

Reiterated

12/08/25

Stifel Nicolaus Remains a Buy on Nurix Therapeutics (NRIX)

Biren Amin

Piper Sandler

$32

Buy

72.79%

Upside

Reiterated

12/08/25

Nurix Therapeutics (NRIX) Gets a Buy from Piper Sandler

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$41

Buy

121.38%

Upside

Reiterated

12/04/25

Nurix Therapeutics (NRIX) Gets a Buy from Jefferies

Brian Abrahams

RBC Capital

$29

Buy

56.59%

Upside

Reiterated

11/19/25

RBC Capital Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

Tessa Romero

J.P. Morgan

$30→$22

Buy

18.79%

Upside

Reiterated

11/18/25

Nurix Therapeutics price target lowered to $22 from $30 at JPMorganNurix Therapeutics price target lowered to $22 from $30 at JPMorgan

David Dai

UBS

$26→$23

Buy

24.19%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)

Matthew Biegler

Oppenheimer

$28

Buy

51.19%

Upside

Reiterated

11/07/25

Nurix Therapeutics (NRIX) Gets a Buy from Oppenheimer

Faisal Khurshid

Leerink Partners

$12

Hold

-35.21%

Downside

Reiterated

10/23/25

Leerink Partners Sticks to Their Hold Rating for Nurix Therapeutics (NRIX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

1 Month

xxx

Success Rate

9/14 ratings generated profit

Average Return

+8.21%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +8.21% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+26.09%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +26.09% per trade.

1 Year

Derek ArchilaWells Fargo

Success Rate

9/14 ratings generated profit

Average Return

+66.27%

reiterated a buy rating 5 days ago

Copying Derek Archila's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +66.27% per trade.

2 Years

xxx

Success Rate

15/19 ratings generated profit

Average Return

+47.41%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +47.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NRIX has received 40 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 27.53.

Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

Next quarter’s earnings estimate for NRIX is -$0.92 with a range of -$1.15 to -$0.73. The previous quarter’s EPS was -$1.03. NRIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.

NRIX Sales Forecast

Next quarter’s sales forecast for NRIX is $13.40M with a range of $0.00 to $24.47M. The previous quarter’s sales results were $7.89M. NRIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Nurix Therapeutics’s 12-month average price target is 27.53.

What is NRIX’s upside potential, based on the analysts’ average price target?

Nurix Therapeutics has 48.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NRIX a Buy, Sell or Hold?

Nurix Therapeutics has a consensus rating of Strong Buy which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.

What is Nurix Therapeutics’s price target?

The average price target for Nurix Therapeutics is 27.53. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $41.00 ,the lowest forecast is $12.00. The average price target represents 48.65% Increase from the current price of $18.52.

What do analysts say about Nurix Therapeutics?

Nurix Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of NRIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

NRIX Analyst Ratings

NRIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nurix Therapeutics

NRIX Analyst Recommendation Trends

NRIX Financial Forecast

NRIX Earnings Forecast

NRIX Sales Forecast

NRIX Stock Forecast FAQ

Detailed List of Analyst Forecasts